Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Apr 01, 2024 12:50pm
100 Views
Post# 35963094

RE:Do we understand what we are voting on ?

RE:Do we understand what we are voting on ?MY  reading  of  the  originally presented proposal  is that  the  NEW  company is entirely owner by  Andrew!

We  will still own  shares  of Replicel  which  will become an  UNLISTED  company  and  become a defacto  'royalty'  company  receiving the  royalty money  (???)  and  will disperse  it to the  shareholders  (of  which all the insiders also  own their Replicel  shares and get  their cut of the 8%  (after  expenses)

So  from  my take  unless someone  pays  millions  for one  of the assets.  we  will get  very little  back  though  Andrew  may  get  some of his  money  back.

Who  knows  maybe he already  has  a behind the scenes deal  for  say  5 or  6  million and be all set already.

GLTA
<< Previous
Bullboard Posts
Next >>